GENE ONLINE|News &
Opinion
Blog

2018-03-13| Asia-Pacific

Bainbridge Investments Bids for Healthcare Industry and Advanced Technology in Taiwan

by GeneOnline
Share To

By Joanne Shih

Nick Chini, Chairman and CEO of Bainbridge Investments, a US direct private equity investments company, stated that Bainbridge is optimistic about investing in Taiwan’s healthcare and entertainment industries and plans to participate in bidding for the Gate of Taipei, a skyscraper development in Taipei, in combination with advanced technologies such as artificial intelligence (AI) and augmented reality (AR). In addition, the strong foundation in medical system and healthcare in Taiwan also attracts Bainbridge to deploy Taiwan’s healthcare market.

Nick said that Bainbridge has evaluated the market in Taiwan for many years and decided to set up three major projects in Taiwan, including bidding for the Gate of Taipei real estate investment, entering healthcare industry, and setting up an AI Forum in Taiwan.

Nick asid, “We not only see the Gate of Taipei real estate investment, but also are optimistic about Taiwan’s high-tech and biotechnology industries.” Therefore, the company plans to invest in the healthcare industry in Taiwan intending to merge the technologies in healthcare and medical care with commercial real estate, leisure facilities, restaurants, department stores, or studios to build a giant hospitality development.

Bainbridge Investments has a professional advisory group for all phases of planning, design and construction, and has extensive experience with projects in the United States, Abu Dhabi and China. Considering the Gate of Taipei as not only a national development but also an important hub for Southeast Asia and Asia, Nick has faith in this investment will bring in more opportunities, and will target on the top 500 companies in the world once they take the bid.

Reference
http://bainbridgeinvestments.com
http://www.chinatimes.com/newspapers/20180312000177-260202

 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
Taiwan’s Biotech Industry Directives: Six Strategic Aspects of AI Empowerment, Smart Healthcare, and Global Expansion
2024-08-29
LATEST
Lotus Pharma Expands in Southeast Asia with Alpha Choay Acquisition from Sanofi
2024-09-06
Indian CDMO Stocks in the Spotlight: US House to Vote on BIOSECURE Act Next Week
2024-09-06
Eli Lilly Joins Forces with AI Startup Genetic Leap in $409M Deal Centered Around RNA-Targeted Drug Discovery
2024-09-06
Illumina Wins EU Court Battle, Dodges Fine, but Grail Deal Already Void
2024-09-05
Breaking New Ground for Clinical Trials with AI/ML Applications
2024-09-05
InMed Pharmaceuticals’ Positive Market Response to Cannabinoid Analog INM-901 for Alzheimer’s Treatment
2024-09-04
Alnylam Pharma Shares Dip Despite Positive Phase 3 HELIOS-B Heart Disease Results
2024-09-04
EVENT
2024-09-11
2024 Bio Asia Pacific
Bangkok, Thailand
2024-09-13
ESMO Congress 2024
Barcelona, Spain
2024-10-09
Medical Japan 2024 Tokyo
Tokyo, Japan
2024-10-15
BIO Investor Forum 2024
San Francisco, U.S.A.
Scroll to Top